

عنوان مقاله:

Investigation of HER-2 expression and its Correlation with clinicopathological parameters and overall survival of esophageal squamous cell carcinoma patients

محل انتشار:

فصلنامه آسیب شناسی ایران، دوره 15، شماره 4 (سال: 1399)

تعداد صفحات اصل مقاله: 8

نویسندگان:

Mitra Heidarpour - *Department of Pathology, Faculty of Medicine, Isfahan University of Medical Sciences, Isfahan, Iran*

Mehran Taheri - *Department of Pathology, Faculty of Medicine, Isfahan University of Medical Sciences, Isfahan, Iran*

Ali Akhavan - *Department of Radiation Oncology, Faculty of Medicine, Isfahan University of Medical Sciences, Isfahan, Iran*

Parvin Goli - *Department of Immunology, Faculty of Medicine, Isfahan University of Medical Sciences, Isfahan, Iran*

Amirhosein Kefayat - *Department of Oncology, Cancer Prevention Research Center, Faculty of Medicine, Isfahan University of Medical Sciences, Isfahan, Iran*

خلاصه مقاله:

Background & Objective: Human epidermal growth factor receptor 2 (HER-2) exhibits a vast range of expression in esophageal squamous cell carcinoma (ESCC) patients as a biomarker. This paper aimed to investigate HER-2 expression and clinicopathological parameters of esophageal SCC. **Methods:** HER-2 expression was assessed in 102 ESCC patients by immunohistochemistry. The HER-2 staining intensity, according to the Gastric HER2 Biomarker 1.0.0.1 version of the college of American pathologists (CAP) protocol for gastric and gastroesophageal junction cancers, was graded as 0 (no reactivity in any of the cancer cells' membranes); 1+ (pale or hardly noticeable reactivity in the membrane of cancer cells' cluster ≥ 5 neoplastic cells) regardless of the positive cancer cells' percentage); 2+ (weak-to-moderate complete, basolateral, or lateral membranous reactivity regardless of the positive cancer cells' percentage); and 3+ (strong complete, basolateral, or lateral reactivity in the membrane of the cancer cell cluster regardless of the positive cancer cells' percentage). In this regard, 3+ scored samples were considered as positive. If HER-2 expression was scored 2+, an additional fluorescence in situ hybridization (FISH) was performed. Fisher's exact test was employed for investigating the correlation of HER-2 expression status with patients' clinicopathological characteristics (including age, gender, tumor location, stage, grade, infiltration level, venous invasion, lymphatic invasion, and tumor recurrence). Kaplan-Meier analysis was done for the patients' survival assessments. **Result:** Five patients (~5%) were HER-2 positive and no significant association was observed between HER-2 expression and clinicopathological properties. In addition, HER-2 expression status exhibited no significant association with the patients' overall survival ($p = 0.9299$). **Conclusion:** HER-2 is not a suitable prognostic biomarker for Iranian ESCC patients.

کلمات کلیدی:

لینک ثابت مقاله در پایگاه سیویلیکا:

<https://civilica.com/doc/1130668>

